179 related articles for article (PubMed ID: 28432084)
1. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.
Roca E; Berruti A; Sbiera S; Rapa I; Oneda E; Sperone P; Ronchi CL; Ferrari L; Grisanti S; Germano A; Zaggia B; Scagliotti GV; Fassnacht M; Volante M; Terzolo M; Papotti M
Endocr Relat Cancer; 2017 Jul; 24(7):319-327. PubMed ID: 28432084
[TBL] [Abstract][Full Text] [Related]
2. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
[TBL] [Abstract][Full Text] [Related]
3. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
4. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
[TBL] [Abstract][Full Text] [Related]
5. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
[TBL] [Abstract][Full Text] [Related]
8. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
[TBL] [Abstract][Full Text] [Related]
9. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
11. Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors.
Monica V; Familiari U; Chiusa L; Rossi G; Novero D; Busso S; Ruffini E; Ardissone F; Scagliotti GV; Papotti M
Lung Cancer; 2013 Mar; 79(3):228-35. PubMed ID: 23276504
[TBL] [Abstract][Full Text] [Related]
12. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
Debets P; Dreijerink KMA; Engelsman A; Dahele M; Haak HR; Steenaard RV; Kapiteijn E; Corssmit E; Menke-van der Houven van Oordt CW
Eur J Cancer; 2024 Jan; 196():113424. PubMed ID: 37977106
[TBL] [Abstract][Full Text] [Related]
13. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
14. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
Sasaki S
Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
[TBL] [Abstract][Full Text] [Related]
15. Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.
Sperone P; Berruti A; Gorzegno G; Paccotti P; Terzolo M; Porpiglia F; Angeli A; Dogliotti L
J Endocrinol Invest; 2006 Jun; 29(6):560-2. PubMed ID: 16840836
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of the association of mitotane with etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical cancer patients. Report on 7 cases.
Pia A; Berruti A; Terzolo M; Paccotti P; Letizia C; Dogliotti L; Angeli A
Ann Oncol; 1995 May; 6(5):509-10. PubMed ID: 7669716
[No Abstract] [Full Text] [Related]
17. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
19. Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.
Berruti A; Terzolo M; Paccotti P; Veglio F; Pia A; Dogliotti L; Angeli A
Tumori; 1992 Oct; 78(5):345-8. PubMed ID: 1494808
[TBL] [Abstract][Full Text] [Related]
20. Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma.
Mangone A; Altieri B; Detomas M; Prete A; Abbas H; Asia M; Elhassan YS; Mantovani G; Ronchi CL
Endocr Relat Cancer; 2023 Apr; 30(4):. PubMed ID: 36715606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
